Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection.
about
Mechanism of Platinum Derivatives Induced Kidney InjuryAn integrated view of cisplatin-induced nephrotoxicity and ototoxicityTempol, a superoxide dismutase mimetic agent, ameliorates cisplatin-induced nephrotoxicity through alleviation of mitochondrial dysfunction in miceUnderstanding the Risk Factors and Long-Term Consequences of Cisplatin-Associated Acute Kidney Injury: An Observational Cohort Study.Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factorsAdvanced hepatocellular carcinoma with hepatic vein tumor thrombosis and renal dysfunction after hepatic arterial infusion chemotherapy effectively treated by liver resection with active veno-venous bypass: report of a case.Ancient Chinese Formula Qiong-Yu-Gao Protects Against Cisplatin-Induced Nephrotoxicity Without Reducing Anti-tumor ActivityImprovement of cisplatin-related renal dysfunction by synthetic ghrelin: a prospective randomised phase II trialPharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy.Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender DifferencesPharmacogenetic analysis of irreversible severe cisplatin-induced nephropathy: a case report of a 27-year-old woman.Multivariate analysis of risk factors for cisplatin-induced nephrotoxicity in gynecological cancer.Magnesium improves cisplatin-mediated tumor killing while protecting against cisplatin-induced nephrotoxicity.Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.Effect of Short Hydration on Cisplatin-Induced Nephrotoxicity in Cancer Patients: A Retrospective Study.Chemical Characterization of a Renoprotective Metabolite from Termite-Associated Streptomyces sp. RB1 against Cisplatin-Induced Cytotoxicity.Influence of magnesium and parathyroid hormone on cisplatin-induced nephrotoxicity in esophageal squamous cell carcinoma.A fully absorbable biomimetic polymeric micelle loaded with cisplatin as drug carrier for cancer therapy.Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin.Plasma ghrelin levels as a predictor of adverse renal events due to cisplatin-based chemotherapy in patients with esophageal cancer.Potential of morin and hesperidin in the prevention of cisplatin-induced nephrotoxicity.Genetic Variations and Cisplatin Nephrotoxicity: A Systematic ReviewThe protective effects of maltol on cisplatin-induced nephrotoxicity through the AMPK-mediated PI3K/Akt and p53 signaling pathways
P2860
Q26783436-91836088-987A-416F-B56C-AD8FDEF02F2BQ28080615-70DE8E10-3326-460B-B960-E89FAD389BC0Q34278299-162471B5-88DA-47ED-A1D7-3281B7DF1967Q35837903-7AB118CF-5B84-4DF1-9C16-D3A3E5B89ECAQ35958459-859F9967-3CFC-4596-B51E-26F485069E8BQ36120874-2439B16C-1B55-4F29-B30B-23BF41883283Q36221657-FE66F892-B0F1-4473-8CBA-76D6502CE183Q37174066-F63396AE-66BB-4C9D-AA4A-EA679F6ED5A3Q38637751-2AA6D864-BD79-40B9-8B2C-E3AE91974C67Q40264602-2F5D59A2-C410-47D2-9D66-1DF0CFB0AED5Q42343539-C98678CB-A0CF-494A-9DE6-8D62DE70B324Q43760668-6624D14B-7AB6-462D-8C82-3AC1EA714EBEQ47250614-395A5483-F2AF-4804-91B0-253BD66F1D0FQ47305361-FFD6F6AB-8179-4BEA-9214-F5D00EDA37D6Q47381902-F8F15A76-F400-4438-B5F9-A4B3E1144F62Q47713536-BEB27157-683D-4B60-8301-B592BF73F87CQ48278478-74CEFC3F-7AFB-40D3-BDC0-DB3D0C8A44D5Q49386919-CEE1B09D-F98F-4BE0-BECD-39CF778A6F16Q49593027-AE57E687-35EB-4907-A6B3-4236AED1BCDFQ50103946-8E9D91B5-2CF5-4C4C-A7A3-8F35BBC496CEQ53186226-5EC7B40C-FA95-4AB9-8A98-66CD9213B156Q54245322-6E1EA0C4-00A0-4AB9-80A5-E65EEE4B7AF3Q57490969-28BD1C20-E1F9-4CEB-8021-BAD5C729886FQ58107281-5804B55E-42FD-40DC-849F-F20A62BE328D
P2860
Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Risk factors for cisplatin-ind ...... entation for renal protection.
@ast
Risk factors for cisplatin-ind ...... entation for renal protection.
@en
type
label
Risk factors for cisplatin-ind ...... entation for renal protection.
@ast
Risk factors for cisplatin-ind ...... entation for renal protection.
@en
prefLabel
Risk factors for cisplatin-ind ...... entation for renal protection.
@ast
Risk factors for cisplatin-ind ...... entation for renal protection.
@en
P2093
P2860
P1433
P1476
Risk factors for cisplatin-ind ...... mentation for renal protection
@en
P2093
Hiroyasu Kaneda
Junji Tsurutani
Kaoru Tanaka
Kazuhiko Nakagawa
Kimiko Fujiwara
Kunio Okamoto
Masayuki Takeda
Morihiro Nomura
Shin-ichi Nishina
Shozo Nishida
P2860
P304
P356
10.1371/JOURNAL.PONE.0101902
P407
P577
2014-07-14T00:00:00Z